Modality
Nanobody
MOA
MDM2i
Target
USP1
Pathway
NF-κB
OCDIgAN
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
Apr 2024
→ May 2028
Phase 1Current
NCT03307772
2,018 pts·OCD
2024-04→2028-05·Not yet recruiting
2,018 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-252.2y awayPh2 Data· OCD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2028-05-25 · 2.2y away
OCD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03307772 | Phase 1/2 | OCD | Not yet recr... | 2018 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| ZEA-9089 | Zealand Pharma | Phase 2/3 | Menin |